Clinical trials: Choroidal NeoVascularization
Macular Degeneration, Age-Related Macular Degeneration
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person.
- Conditions
- Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
- Trial name
- MALBEC (NCT07440225)
- Testing
- Tiespectus, Aflibercept
- Where
- 132 sites in United States, Argentina and 10 more
- Volunteers
- 960 people
- Sponsor
- EyeBiotech Ltd.
Age-related Macular Degeneration
Eyes That Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the Real-World Patient Population and Reasons for Exclusion
The purpose of the present study was to evaluate the proportion of eyes that do not meet the eligibility criteria of clinical trials on neovascular AMD among the entire sample of eyes diagnosed with treatment-naïve neovascular…
- Trial name
- NCT04836143
- Testing
- Intravitreal anti-vascular endothelial growth factor injection
- Where
- South Korea
- Volunteers
- 512 people
- Sponsor
- Kim's Eye Hospital
Macular Degeneration, Choroidal Neovascularization
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
To evaluate the safety and efficacy of the combination treatments in wet age-related macular degeneration. The combination treatment consists of verteporfin photodynamic therapy and either triamcinolone acetonide or pegaptanib…
- Trial name
- VERITAS (NCT00242580)
- Testing
- Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Novartis Pharmaceuticals
Age-related Macular Degeneration
Characterization of Early Markers of Choroidal Neovascularization
To this study and identify the sequence of alterations occurring in the chorioretinal interface during progression of AMD from "dry" AMD to sight-threatening chorioretinal neovascularization (CNV).
- Trial name
- CNV-Markers (NCT00801541)
- Where
- Portugal
- Volunteers
- 60 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
PCV, Polypoidal Choroidal Vasculopathy
Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)
This is a 24-month study of ranibizumab (2.0 mg and 1.0 mg) in subjects with polypoidal choroidal vasculopathy as diagnosed by fluorescein/indocyanine green (FA/ICG) angiography.
- Trial name
- PEARL2 (NCT01884597)
- Testing
- high-dose ranibizumab, ranibizumab
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Hawaii Pacific Health
Macular Degeneration
Identification and Treatment of Feeder Vessels in Macular Degeneration
This study will try to identify and treat feeder vessels in age-related macular degeneration. The macula is the part of the retina in the back of the eye that determines central or best vision.
- Trial name
- NCT00018070
- Testing
- Angiography, Laser Treatment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Eye Institute (NEI)
Neovascular Age-related Macular Degeneration
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Neovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of…
- Trial name
- NCT05536973
- Testing
- ADVM-022
- Where
- 39 sites in United States, France and 1 more
- Volunteers
- 69 people
- Sponsor
- Adverum Biotechnologies, Inc.